Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA043 in primary osteoarthritis
NCT02491281Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing LNA043 with Placebo (2 arms). Primary endpoint: Safety endpoints (adverse events, physical exam, vital signs, ECG, safety laboratory, pain). Started Nov 2015; status: completed.
02
Drugs
LNA043
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02491281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491281.